Clinical trial · Interventional
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
NCT01535053CI-TRIAL-00060281completedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in chemotherapy, such as methotrexate and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether methotrexate is more effective than dactinomycin in treating gestational trophoblastic disease.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Choriocarcinoma | Choriocarcinoma | ONTOLOGY_EXACT | 0.90 |
| FIGO Stage I Gestational Trophoblastic Tumor | — | UNRESOLVED | — |
| FIGO Stage II Gestational Trophoblastic Tumor | — | UNRESOLVED | — |
| FIGO Stage III Gestational Trophoblastic Tumor | — | UNRESOLVED | — |
| Hydatidiform Mole | Molar Pregnancy | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dactinomycin | Biological | Dactinomycin | ALIAS |
| Leucovorin Calcium | Drug | Leucovorin | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (dactinomcin)
- description
- Patients receive dactinomycin IV over 15 minutes on day 1.
- interventionNames
- Biological: Dactinomycin
- Other: Quality-of-Life Assessment
- type
- ACTIVE_COMPARATOR
- label
- Arm II (leucovorin calcium and methotrexate)
- description
- Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
- interventionNames
- Drug: Leucovorin Calcium
- Drug: Methotrexate
- Other: Quality-of-Life Assessment
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Patients who meet International Federation of Gynecology and Obstetrics (FIGO) stage I, II, or III criteria for low-risk gestational trophoblastic neoplasia (GTN): post molar GTN or choriocarcinoma (as defined below); patients may have had a second curettage but must still meet GTN criteria below:
* Post molar GTN
* For the purposes of this study, patients must have undergone evacuation of a complete or partial hydatidiform mole and then meet the criteria for GTN defined as:
* A \< 10% decrease in the hCG level using as a reference the first value in the series of 4 values taken over a period of 3 weeks (\> 50 mIU/ml minimum) OR
* A \> 20% sustained rise in the hCG taking as a reference the first value in the series of 3 values taken over a period of 2 weeks (\> 50 mIU/ml minimum) OR
* A persistently elevated hCG level a period of 6 months or more following the initial curettage (\> 50 mIU/ml minimum)
* Choriocarcinoma
* Histologically proven non-metastatic choriocarcinoma OR
* Histologically proven metastatic choriocarcinoma if the metastatic site(s) is restricted to one (or more) of the following: vagina, parametrium, or lung
* World Health Organization (WHO) risk score 0-6
* Patients must be willing to practice effective contraception for the duration of the study
* White blood cell count (WBC) \>= 3,000 cells/mcL
* Granulocytes \>= 1,500/mcL
* Platelets \>= 100,000/mcL
* Creatinine =\< 2.0 mg/dcL
* Bilirubin =\< 1.5 x institutional normal
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x institutional normal
* Alkaline phosphatase =\< 3 x institutional normal
* Patients who have met the pre-entry requirements
* Before enrolling a patient, the institution must verify the availability of an adequate supply of methotrexate for a full course of therapy
* Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
* Patients who do not have GTN
* Patients with non-gestational choriocarcinoma
* Patients who have previously been treated with cytotoxic chemotherapy; however, patients who received prior low-dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study
* Patients who have received prior pelvic radiation
* Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)
* Patients with Gynecologic Oncology Group (GOG) performance status of 3 or 4
* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
* Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up
* Patients who wish to breast-feed during treatmentReferences
Publications (1)
- DERIVEDSchink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, Anderson N, Moxley K, Yabuno A, Taylor SE, Kushnir C, Horowitz N, Miller DS. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol. 2020 Aug;158(2):354-360. doi: 10.1016/j.ygyno.2020.05.013. Epub 2020 May 24. PMID 32460997